Form 4: Achieve Life Sciences Executive Acquires Stock Options
SEC Form 4 Filing
Jaime Xinos, Chief Commercial Officer of Achieve Life Sciences, was granted 20,000 stock options on January 13, 2025.
Summary
- Jaime Xinos, the Chief Commercial Officer of Achieve Life Sciences, was granted 20,000 stock options.
- The options have an exercise price of $3.32 per share.
- The options vest over a period of 4 years, with 1/4 vesting on the first anniversary of December 6, 2024, and the remainder vesting monthly over the following 36 months.
- The options expire on January 13, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.
Positives
- The granting of stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Risks
- The value of the options is dependent on the future performance of the company's stock price.
- If the stock price does not increase above the exercise price, the options will have no value.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech sector.
- The vesting schedule of 4 years is typical for such grants, ensuring long-term commitment.
- The exercise price is set at the market price at the time of the grant, which is standard practice.
Stakeholder Impact
- Shareholders may view this positively as it incentivizes management to increase the company's value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 2024-12-06 | Date from which the vesting schedule is calculated. |
| 2025-01-13 | Date of the stock option grant. |
| 2025-01-14 | Date of the filing of the SEC Form 4. |
| 2035-01-13 | Expiration date of the stock options. |
Keywords
stock options, executive compensation, insider trading, vesting, ACHV, Achieve Life Sciences
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.